Radioimmunodiagnosis and therapy

Cancer Treatment Reviews

Volumn 26, Issue 1, 2000, Pages 3-10

  Verhaar Langereis, M J ^a   Zonnenberg, B A ^a   De Klerk, J M H ^a   Blijham, G H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Monoclonal antibodies; Radioimmunodiagnosis; Radioimmunotherapy; Radionuclides; ScFv

Indexed keywords

CANCER ANTIBODY; CYCLOSPORIN A; RADIOISOTOPE;

HUMAN; MATHEMATICAL MODEL; RADIOIMMUNOTHERAPY; REVIEW; SOLID TUMOR;

EID: 0033953266     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.1999.0146     Document Type: Review

References (107)

1. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:1975;495-497.
2. Epenetos A. A., Mather S., Granowska M. Targeting of I-123 labelled tumour associated monoclonal antibodies to ovarian, breast and gastro-intestinal tumours. Lancet. 6:1982;999-1004.
3. Anderson W. I., Strand M. Radiolabelled antibody: iodine versus radiometal chelates. NCI monogr. 3:1987;149-151.
4. DeNardo S. J., DeNardo G. L., O'Grady L. F. Pilot studies of radioimmunotherapy of B cell lymphoma and leukaemia using I-131 Lym-1 monoclonal antibody. Antibody Immunoconjugates Radiopharmaceut. 1:1988;17.
5. Vitetta E. S., Stone M., Amlot P. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 51:1991;4052-4058.
6. Pai L. H., Batra J. K., Fitzgerald D. J. Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxins. Proc Natl Acad Sci USA. 88:1991;3358-3362.
7. Goldenberg D. M., Kim E. E., Bennet S. J. Carcinoembryonic antigen radioimmunodetection in the evaluation of colorectal cancer and in the detection of occult neoplasms. Gastroenterology. 84:1983;524-532.
8. Riethmuller G., Schneider-Gadicke E., Schlimok G. Randomised trial of monoclonal antibody antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet. 343:1994;1177-1183.
9. Riethmuller G., Holz E., Schlimok G. Monoclonal antibody therapy for resected Dukes C colorectal Cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol. 16:1998;1788-1794.
10. Miller R. A., Maloney D. G., Warnke R. Treatment of B cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 306:1982;517-522.
11. Press O. W., Eary J. F., Badger C. C. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol. 7:1989;1027-1038.
12. 131I) anti-B1 (anti CD-20) antibody. N Engl J Med. 329:1993;459-465.
13. DeNardo S. J., DeNardo G. L., Kukis D. L. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation, dosimetry, toxicity and tumor regression in patients with lymphoma. J Nucl Med. 40:1999;302-310.
14. Knox S. J. Radioimmunotherapy of the non-Hodgkins lymphoma's. Sem.Radiat. Oncol. 5:1995;331-334.
15. Juweid M., Swayne L. C., Sharkey R. M. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131 labeled murine and humanized MN-14 anticarcinoembryonic antigen monoclonal antibodies. Gynecol-Oncol. 67(3):1997;259-271.
16. Amlot P. L., Stone M. J., Cunningham D. A phase I study of an anti-CD-22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood. 82:1993;2624-2633.
17. Bagshaw K. D., Sharma S. K., Springer C. J. Antibody directed prodrug therapy: a pilot-scale clinical trial. Tumor Targeting. 1:1995;17-29.
18. Baxter L. T., Zhu H., Mackensen D. G. Biodistribution of monoclonal antibodies: Scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res. 55:1995;4611-4522.
19. Mach J. P., Carrell S. E., Forni M. Tumor localization of radiolabelled antibodies against carcinoembryonic antigen in patients with carcinoma. N Engl J Med. 303:1980;5-10.
20. Esteban J. M., Colcher D., Sugarbaker P. Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered Mab B72.3. Int. J. Cancer. 39:1987;50-59.
21. Jain R. K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 50:1990;814S-819S.
22. Carrasquillo J. A., Abrams P. G., Schroff R. W. Effect of antibody dose on the imaging and biodistribution of indium-111 9.2.27 anti-melanoma monoclonal antibody. J Nucl Med. 29:1988;39-47.
23. Pimm M. V., Perkins A. C., Armitage N. C. The characterisitics of blood-borne radiolabels and the effect of anti-mouse IgG antibodies on localisation of radiolabelled monoclonal antibody in cancer patients. J Nucl Med. 26:1985;1011-1023.
24. Rosen S. T., Zimmer A. M., Goldman-Leikin R. Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphoma using a 131I labelled monoclonal antibody: An Illinois Cancer Council Study. J Clin Oncol. 5:1987;562-573.
25. Meredith R. F., Khazaeli M. B., Liu T. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med. 33:1992;1648-1653.
26. DeNardo S. J., DeNardo G. L., Lamborn K. R. Enhancement of tumor uptake of monoclonal antibody in nude mice with PEG-I1-2. Antib Immunoconjug Radiopharm. 4:1991;859-870.
27. Baxter L. T., Jain R. K., Svensio E. Vascular permeability and interstitial diffusion of macromolecules in the hamster cheek pouch: effects of vasoactive drugs. Microvasc Res. 34:1987;336-348.
28. Denardo G I., Kukis D. L., Denardo S. J. Enhancement of 67Cu-2IT-BAT-Lym-I therapy in mice with human Burkitt's lymphoma using I1-2. Cancer. 80(12suppl):1997;2576-2582.
29. Hornick J. L., Khawli L. A., Sharif J. Pretreatment with a monoclonal antibody/IL-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumours. Clin Cancer Res. 5(1):1999;51-60.
30. King D. J., Mountain A., Adair J. R. Tumor localization of engineered antibody fragments. Antibody, immunoconjugates, and radiopharmaceuticals. 5:1992;159-170.
31. Colcher D., Bird R., Roselli M. In vivo tumor targeting of a recombinant single-chain antigen binding protein. J Nalt Cancer Inst. 79:1990;1393-1401.
32. Yokota T., Milenic D. E., Whitlow M. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52:1992;3402-3408.
33. Yokota T., Milenic D. E., Whitlow M. Microaudiographic analysis of the normal organ distribution of radionated single-chain Fv and other immunoglobulin forms. Cancer Res. 53:1993;3776-3783.
34. Bird R. E., Hardman K. D., Jacobson J. W. Single-chain antigen binding proteins. Science. 242:1988;423-426.
35. Milenic D. E., Yokota T., Filpula D. R. Construction, binding properties, metabolism, and targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 51:1991;6363-6371.
36. Williams W. V., Moss D. A., Kieber-Emmons T. Development of biologically active peptides based on antibody structure. Proc Natl Acad Sci USA. 86:1989;5537-5541.
37. Chester K. A., Begent R. H., Robson L. A new way to generate clinically useful antibodies. Lancet. 343:1994;55.
38. Reilly R. M. Radioimmunotherapy of malignancies. Clin Pharm. 10:1991;359-375.
39. Begent R. H. J., Ledermann J. A., Green A. Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer. Br J Cancer. 60:1989;406-412.
40. Marshall D., Pedley R. B., Boden J. A. Clearance of circulating radio-isotopes using streptavidin or second antibodies in a xenograft model. Br J Cancer. 69(3):1994;502-507.
41. 131I-labeled antibody to carcinoembryonic antigen in cancer radioimmunotherapy. J Natl Cancer Inst. 81:1989;19-49.
42. Malamitsij J., Skarlos D., Fotiou S. Intracavitary use of two radiolabeled tumor-associated monoclonal antibodies. J Nucl Med. 29:1988;1910-1915.
43. Epenetos A. A. Antibody-guided irradiation of malignant lesions; Three cases illustrating a new method of treatment. Lancet. 11:1984;1441-1443.
44. Schlom J., Horan Hand P., Greiner J. W. Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting. Cancer Res (suppl). 50:1990;820s-827s.
45. Begent R. H. J., Verhaar M. J., Chester K. A. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nature Med. 2(9):1996;979-984.
46. Larson S. M., El-Shirbiny A. M., Divgi C. R. Single chain antigen binding protein (sFv CC49). First human studies in colorectal metastatic to liver. Cancer. 80:1997;2458-2468.
47. Schlom J., Eggensperger D., Colcher D. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res. 52:1992;1067-1072.
48. Velders M. P., Litvinov S. V., Warnaar S. O. New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res. 54:1994;1753-1759.
49. Pullyblank A. M., Monson R. T. Monoclonal antibody treatment of colorectal cancer. Br J Surgery. 84:1997;1511-1517.
50. Osbourne J. K., Field A., Wilton J. Generation of a panel of related scFv antibodies with high affinities for human CEA. Immunotechnology. 2(3):1996;181-196.
51. Behr T. M., Sharkey R. M., Juweid M. E. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies. J Nucl Med. 38(3):1997;409-418.
52. Begent R. H.J., Chester K. A. Single-chain Fv antibodies for targeting cancer therapy. Biochem Soc Trans. 25(2):1997;715-717.
53. Thomas G. D., Chappell M. J., Dykes P. W. Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody or ligand: a biomathematical model. Cancer Res. 49:1989;3290-3296.
54. Weiner L. M., Holmes M., Adams G. P. A human tumor xenograft model of therapy with abispecific monoclonal antibody targeting c-erB-2 and CD16. Cancer Res. 53:1993;94-100.
55. Gautherot E., Bouhou J., Le-Doussal J. M. Therapy for colon carcinoma xenografts with bispecific antibody-targeted iodine-131-labeled bivalent hapten. Cancer. 80(12):1997;2618-2623.
56. Kraeber-Bodere F., Faivre-Chauvet A., Sai-Maruel C. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft. J Nucl Med. 40:1999;198-204.
57. Guadagni F., Witt P. L., Robbins P. F. Regulation of carcinoembryonic antigen expression in different human colorectal tumour cells by interferon-gamma. Cancer Res. 50:1990;6248-6255.
58. Wilder R. B., Langmuir V. K., Medonca H. L. Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts. Cancer Res. 53:1993;3022-3027.
59. Greiner J. W., Guadagni F., Horan Hand P. Augmentation of tumor antigen expression by recombinant human IFNs: enhanced targeting of monoclonal antibodies to carcinomas. Goldenberg D. M. Cancer imaging with radiolabelled antibodies. 1990;413-432 Norwell, MA, Nijhoff.
60. Roselli M., Guadagni F., Buonomo A. Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma- associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen. J. Clin. Oncol. 14(7):1996;2031-2042.
61. Dansky Ullmann C., Salgaller M., Adams S. Synergistic effects of I1-6 and IFN-gamma on carcinoembryonic antigen (CEA) and HLA expression by human colorectal carcinoma cells; role for endogenous IFN-beta. Cytokine. 7(2):1995;118-129.
62. Dorudi A., Northover J. M. A., Vile R. G. Gene transfer therapy in cancer. Br J Surgery. 80:1993;566-572.
63. Raben D., Buchsbaum D. J., Khazaeli M. B. Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene. Gene therapy. 3:1996;567-580.
64. Ledermann J. A., Begent R. H. J., Bagshawe K. D. Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A. Br J Cancer. 58:1988;654-657.
65. Courtenay-Luck N. S., Epenetos A. A., Moore R. Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res. 46:1986;6489-6493.
66. Wilder R. B., DeNardo G. L., DeNardo S. L. Radioimmunotherapy: Recent results and future directions. J Clin Oncol. 14(4):1996;1383-1400.
67. Kuus-Rachel K., Graver L. S., Korawvodin L. M. Will immunogenicity limit the use, efficacy and future development of therapeutic monoclonal antibodies. Clinical and Diagnostic laboratory immunology. 1(4):1994;365-372.
68. Kosmas C., Epenetos A. A., Courtenay-Luck N. S. Patients receiving murine monoclonal antibody therapy for malignancy develop T cells, that proliferate in vitro in response to the antibodies as antigen. Br J Cancer. 64:1991;494-500.
69. Schultes B. C., Yang R., Agopsowicz K. Anti-idiotype induction therapy for ovarian cancer: immune responses in patients injected with Ovarex ™ Mab-B43.13. Proc ASCO. 1999;1399.
70. Ledermann J. A., Begent R. H. J., Massof C. A phase 1 study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to suppress the immune response. Int J Cancer. 47:1990;659-664.
71. Begent R. H. J., Ledermann J. A., Bagshawe K. D. Dosimetry and immunogenicity of radioimmunotherapy with chimeric B72.3 antibody in colorectal cancer. Advances in the applications of monoclonal antibodies in Clinical Oncology. 1991;57.
72. Hale G., Clark M. R., Marcus R. Remission induction in non-Hodgkin's lymphoma with reshaped human monoclonal antibody CAMPATH-1. Lancet. 11:1988;1394-1399.
73. Hird V., Verhoeyen M., Badley R. A. Tumour localisation with a radioactivity labelled reshaped human monoclonal antibody. Br J cancer. 64:1991;911-914.
74. Huston J. S., George A. J. T., Adams G. P. Single-chain Fv radioimmunotargeting. The Quartely J Nucl Med. 40(3):1996;320-333.
75. Karmochkine M., Bussel A., Leon A. Long term plasma exchange. Analysis of indications, outcome and side effects. Annales de Medicine Interne. 145(5):1993;373-375.
76. Verhaar M. J., Chester K. A., Keep P. A. A single chain Fv derived from a filamentous phage library has distinct tumour targeting advantages over one derived from a hybridoma. Int J Cancer. 61:1995;497-501.
77. Clackson T., Hoogenboom H. R., Griffiths A. D. Making antibody fragments using phage display libraries. Nature. 352:1991;624-628.
78. 99 mTc radiolabelling using a phage-derived single chain Fv with a C-terminal cysteine for colorectal tumour imaging. J. Nucl. Med. 37(5):1996;868-872.
79. Turner D. J., Ritter MA and George A. J. T. Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology. J Immunol Methods. 205:1997;43-54.
80. Whitlow M., Bell B. A., Feng S. L. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng. 6:1993;989.
81. Pietersz G. A., Patrick M. R., Chester K. A. Preclinical characterization and in vivo imaging studies of an engineered recombinant technetium-99 m-labeled metallothionein-containing anti-carcinoembryonic antigen single-chain antibody. J Nucl Med. 39(1):1998;47-56.
82. McCartney J. E., Tai M. S., Oppermann H. Refolding of a single-chain Fv with cterminal cysteine (scFv): Formation of disulfide bonded homodimers of anti-c-erbB-2 and anti-digoxin sFv. Miami Short Reports. 3:1993;91.
83. Michael N. P., Chester K. A., Melton R. G. In vitro and in vivo characterisation of a recombinant carboxypeptidase G2: anti-CEA scFv fusion protein. Immunotechnology. 2(1):1996;47-57.
84. Eldin P., Pauza M. E., Hieda Y. high-level secretion of two antibody single chain Fv fragments by Pichia pastoris. J Immunol Methods. 201:1997;67-75.
85. Nourigat C., Badger C. C., Bernstein I. D. Treatment of lymphoma with radiolabelled antibody; Elimination of tumor cells laking target antigen. J Natl Cancer. 82:1990;47-50.
86. Zalutsky M. R., Gard P. K., Friedman H. S. Labeling monclonal antibodies and F(ab')2 fargments with the alpha-particle emitting nuclide astatine-211. Preservation of immunoreactivity and in vivo localizing capacity. Proc Natl Acad Sci USA. 86:1989;7149-7153.
87. Daghighian F., Pentlow K. S., Larson S. M. Development of a method to measure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: Positron emission tomography studies of iodine-125 labelled 3F8 monoclonal antibody in glioma. Eur J Nucl Med. 20:1993;402-409.
88. Beekman F. J., Kamphuis C., Viergever M. A. Improved SPECT quantitation using fully three-dimensional iterative spatially variant response compensation. IEEE Trans on Med Imaging. 15:1996;491-499.
89. 2and Fab' in mice. Cancer Res. 46:1986;3969-3978.
90. Howell R. W., Rao D. V., Sastry K. S. R. Macroscopic dosimetry for radioimmunotherapy: non-uniform activity distributions in solid tumors. Med Phys. 16:1989;66-74.
91. Sharkey R. M., Blumenthal R. D., Behr T. M. Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma. Int J Cancer. 72:1997;477-485.
92. Rao D. V., Howell R. W. Time-dose fractionation in radioimmunotherapy: implications for selecting radionuclides. J. Nucl. Med. 34:1993;1801-1810.
93. Moi M. K., DeNardo S. J., Meares C. F. Stable bifunctional chelates of metals used in radiotherapy. Cancer Res. 50:1990;789s-793s.
94. Kosmas C., Snook D. E., Gooden C. S. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunconjugates for imaging and therapy. Cancer Res. 52:1992;904-911.
95. Stewart J. S. W., Hird V., Snook D. Intraperitoneal Yttrium-90 labeled monoclonal antibody in ovarium cancer. J Clin Oncol. 8:1990;1941-1950.
96. Rowlinson-Busza G., Snook D., Epenetos A. A. 90Y-labeled antibody uptake by human tumor xenografts and the effect of systemic administration of EDTA. Int J Radiat Oncol Biol Phys. 28(5):1994;1257-1265.
97. 67Cu-2IT-BAT-Lym-1 for frationated radioimmunotherapy of Non-Hodgkin's lymphoma: a pilot study. Anticancer Research. 18:1998;2779-2788.
98. Maxon H. R., Schroder L. E., Thomas S. R. Re-186(Sn)HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormonal-resistant prostate cancer. Radiology. 176:1990;155-159.
99. 186Re-etidronate in breast cancer patients with metastatic bone pain. J Nucl Med. 40:1996;639-642.
100. Quirijnen J. M. S. P., Han S. H., Zonnenberg B. A. Efficacy of Rhenium-186-etidronate in prostate cancer patients with metastatic bone pain. J Nucl Med. 37:1996;1511-1515.
101. Breitz H. B., Weiden P. L., Vanderheyden J. L. Clinical experience with rhenium-186 labeled monoclonal antibodies for radioimmunotherapy: results of phase 1 trials. J Nucl Med. 33:1992;1099-1112.
102. Griffiths G. L., Goldenberg D. M., Diril H. Technetium-99 m, Rhenium-186, and Rhenium-188 direct-labeled antibodies. Cancer. 73:1994;761-768.
103. Zhu H., Baxter L. T., Jain R. K. Potential and linitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies. J Nucl Med. 38:1997;731-741.
104. Hellman S. Priciples of radiation therapy. Rosenberg S. A., Hellman S., DeVito V. Cancer. 1992.
105. Fowler J. F. Radiobiological aspects of low dose rates in radioimmunotherapy. Int. J. Radiation Oncology. Biol Phys. 18:1990;1261-1269.
106. Zhu H., Jain R. K., Baxter T. tumor pretargeting for radioimmunodetection and radioimmunotherapy. J. Nucl Med. 39 (1):1998;65-76.
107. Cremonesi M., Ferrari M., Chinol M. Three-step radioimmunotherapy with yttrium-90-biotin: dosimetry and pharmacokinetics in cancer patients. Eur J Nucl Med. 26:1999;110-120.